Reports for TEVA CANADA LIMITED
Company Name
TEVA CANADA LIMITED
Totals |
||
Shortage reports |
3192 |
|
| Actual shortage: | 254 (8%) | |
| Anticipated shortage: | 1 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 2927 (92%) | |
Discontinuation Reports |
435 |
|
| To be discontinued: | 2 (0%) | |
| Discontinued: | 410 (94%) | |
| Reversed: | 23 (5%) | |
Late reports |
482 (13%) |
|
Overdue reports |
11 (4%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| TEVA-TOPIRAMATE | 100MG | TABLET | Resolved | 2023-07-20 | 2023-10-04 | 199345 |
| TEVA-TOPIRAMATE | 200MG | TABLET | Resolved | 2023-10-05 | 2024-01-25 | 206398 |
| TEVA-TOPIRAMATE | 25MG | TABLET | Resolved | 2024-04-11 | 2024-05-23 | 224889 |
| TEVA-TOPIRAMATE | 100MG | TABLET | Resolved | 2025-03-13 | 2025-08-08 | 252584 |
| TEVA-TOPIRAMATE | 200MG | TABLET | Resolved | 2025-07-18 | 2025-08-21 | 263131 |
| TEVA-TOPISONE | .05% | CREAM | Resolved | 2020-01-24 | 2020-02-21 | 104362 |
| TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2020-01-24 | 2020-02-13 | 104368 |
| TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2020-09-11 | 2020-10-01 | 124107 |
| TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2021-01-07 | 2021-02-18 | 131060 |
| TEVA-TOPISONE | 0.05% | CREAM | Resolved | 2021-08-27 | 2021-09-16 | 144721 |
| TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2022-01-20 | 2022-03-24 | 153147 |
| TEVA-TOPISONE | 0.05% | CREAM | Resolved | 2022-01-20 | 2022-03-09 | 153150 |
| TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2022-04-21 | 2022-06-17 | 159192 |
| TEVA-TOPISONE | 0.05% | CREAM | Resolved | 2022-06-09 | 2022-08-20 | 162277 |
| TEVA-TOPISONE | 0.05% | OINTMENT | Resolved | 2022-12-01 | 2022-12-15 | 176800 |
| TEVA-TOPISONE | 0.05% | CREAM | Resolved | 2023-11-03 | 2023-12-14 | 209116 |
| TEVA-TOPISONE | 0.05% | LOTION | Resolved | 2023-11-03 | 2023-12-14 | 209119 |
| TEVA-TOPISONE | 0.05% | CREAM | Resolved | 2024-02-29 | 2024-07-18 | 220992 |
| TEVA-TOPISONE | 0.05% | LOTION | Resolved | 2024-03-21 | 2024-06-29 | 222944 |
| TEVA-TOPISONE | 0.05% | LOTION | Resolved | 2024-04-18 | 2024-06-29 | 225480 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| PIPERACILLIN / TAZOBACTAM POWDER FOR INJECTION | 0.5G 4G | POWDER FOR SOLUTION | Discontinued | 2023-11-15 | 2023-11-15 | 210194 |
| PIPERACILLIN / TAZOBACTAM POWDER FOR INJECTION | 4G 0.5G | POWDER FOR SOLUTION | Discontinued | 2025-05-28 | 2025-05-28 | 258717 |
| RATIO-ATORVASTATIN | Discontinued | 2018-10-17 | 2018-10-17 | 64589 | ||
| RATIO-ATORVASTATIN | Discontinued | 2018-10-17 | 2018-10-17 | 64592 | ||
| RATIO-ATORVASTATIN | Discontinued | 2018-10-17 | 2018-10-17 | 64615 | ||
| RATIO-ATORVASTATIN | Discontinued | 2018-10-17 | 2018-10-17 | 64623 | ||
| RATIO-ATORVASTATIN | Discontinued | 2018-10-17 | 2018-10-17 | 64626 | ||
| RATIO-ATORVASTATIN | Discontinued | 2018-10-19 | 2018-10-19 | 64852 | ||
| RATIO-FENOFIBRATE MC | 200MG | CAPSULE | Discontinued | 2018-10-12 | 2018-10-12 | 63943 |
| RATIO-FENOFIBRATE MC | 200MG | CAPSULE | Discontinued | 2018-10-19 | 2018-10-19 | 64891 |
| TEVA-LENOLTEC NO. 1 | 300MG 8MG 15MG | TABLET | Discontinued | 2019-04-11 | 2019-04-11 | 81362 |
| RATIO-MEMANTINE | Discontinued | 2018-10-17 | 2018-10-17 | 64595 | ||
| RATIO-MEMANTINE | Discontinued | 2018-10-17 | 2018-10-17 | 64598 | ||
| RATIO-METFORMIN | 850MG | TABLET | Discontinued | 2020-07-10 | 2020-07-10 | 120012 |
| RATIO-NYSTATIN | 100000UNIT | CREAM | Discontinued | 2019-10-25 | 2019-10-26 | 97243 |
| RATIO-NYSTATIN | 100000UNIT | CREAM | Discontinued | 2019-10-25 | 2019-10-26 | 97261 |
| RATIO-NYSTATIN | 100000UNIT | CREAM | Discontinued | 2020-02-13 | 2020-02-13 | 106148 |
| RATIO-SALBUTAMOL | Discontinued | 2020-02-13 | 2020-02-13 | 106151 | ||
| RATIO-TAMSULOSIN | 0.4MG | CAPSULE (SUSTAINED-RELEASE) | Discontinued | 2018-10-19 | 2018-10-19 | 64917 |
| RATIO-TOPISALIC | 20MG 0.5MG | LOTION | Discontinued | 2024-06-28 | 2024-06-29 | 231583 |